XBiotech
XBIT
47 hedge funds and large institutions have $51.4M invested in XBiotech in 2019 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 28 increasing their positions, 4 reducing their positions, and 5 closing their positions.
600% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 4
80% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 5
54% more capital invested
Capital invested by funds: $33.4M → $51.4M (+$18M)
9% more funds holding
Funds holding: 43 → 47 (+4)
1.22% more ownership
Funds ownership: 10.77% → 11.98% (+1.2%)
100% less call options, than puts
Call options by funds: $5K | Put options by funds: $1.03M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Northern Trust
Chicago,
Illinois
|
+$1.27M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
+$1.15M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$880K |
| 4 |
State Street
Boston,
Massachusetts
|
+$624K |
| 5 |
BlackRock
New York
|
+$611K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
-$1.61M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$249K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$146K |
| 4 |
Tudor Investment Corp
Stamford,
Connecticut
|
-$103K |
| 5 |
ARTA
A.R.T. Advisors
New York
|
-$101K |
XBIT Hedge Fund Activity: Q3 2019 in Review
47 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in XBiotech (XBIT) for Q3 2019, worth a combined $51.4M — up 54% from $33.4M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new XBIT positions and 5 closed out — a net gain of 4 holders — while 28 added to existing stakes and 4 trimmed.
The largest buyer was Northern Trust, adding an estimated $1.27M. The largest seller was Balyasny Asset Management, exiting entirely with an estimated $1.61M sold.
- 47 institutional investors held XBiotech (XBIT) as of Q3 2019, up from 43 in Q2 2019.
- Funds reported $51.4M of XBiotech stock for Q3 2019, up 54% quarter-over-quarter.
- 9 funds opened new XBiotech positions in Q3 2019 and 5 closed out, a net change of +4 holders.
- The largest XBiotech buyer in Q3 2019 was Northern Trust, an estimated $1.27M added.
- The largest XBiotech seller in Q3 2019 was Balyasny Asset Management, an estimated $1.61M sold.
Based on aggregated 13F filings for Q3 2019.